s Recent Advances of 2-Quinolone-Based Derivatives as Anti-Tubercular Agents

The WHO has estimated that one-fourth of the world's population harbor a latent infection by MTB, and around 100-200 million individuals eventually develop an active TB. To make matters worse, drug-resistant MTB as well as the co-infection between MTB and HIV has further aggravated the mortality and spread of this disease. The quinolones have contributed an increasingly important chapter to the evolution of antimicrobials, and some of them were recommended as the second-line agents for the treatment of TB by WHO. Numerous 2-quinolone-based derivatives have been synthesized for searching new anti-TB agents, and some of them showed promising potency. This review aims to outline the recent advances made towards the discovery of 2-quinolone-based derivatives as potential anti-TB agents, and their structure-activity relationships are also discussed.